Clinical Research Directory
Browse clinical research sites, groups, and studies.
Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure
Sponsor: Hunan Cancer Hospital
Summary
This study is an open-label, multicenter, single-arm Phase II clinical study to evaluate the effectiveness of cadonilimab (AK104) in combination with anlotinib in the treatment of locally advanced or metastatic melanoma.
Official title: Efficacy and Safety of Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure: A Single-arm, Open-label, Multicenter Phase II Clinical Study
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2024-05-15
Completion Date
2027-05-31
Last Updated
2024-03-25
Healthy Volunteers
No
Conditions
Interventions
Cadonilimab
Injectable solution
anlotinib
capsule